BIONDVAX PHARMACEUTICALS-ADR (BVXV) Forecast, Price Target & Analyst Ratings

NASDAQ:BVXV • US09073Q2049

Current stock price

1.36 USD
+0.05 (+3.82%)
At close:
1.38 USD
+0.02 (+1.47%)
After Hours:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for BIONDVAX PHARMACEUTICALS-ADR (BVXV).

Forecast Snapshot

Consensus Price Target

Price Target
$39.78
+ 2,825.00% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
N/A
Period
Q3 / 2023
EPS Estimate
-$1.01
Revenue Estimate
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
82.86%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$39.78
Upside
+ 2,825.00%
From current price of $1.36 to mean target of $39.78, Based on 7 analyst forecasts
Low
$8.08
Median
$39.78
High
$73.50

Price Target Revisions

1 Month
0.00%
3 Months
0.00%

Price Target Summary

7 Wall Street analysts provided a forecast for the next 12 months for BVXV. The average price target is 39.78 USD. This implies a price increase of 2825% is expected in the next year compared to the current price of 1.36.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

BVXV Current Analyst RatingBVXV Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 0 0 0 0 0

Analyst Ratings History

BVXV Historical Analyst RatingsBVXV Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 2 4 6

Analyst Ratings Consensus

ChartMill Buy Consensus
82.86%
BVXV was analyzed by 7 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about BVXV.
In the previous month the buy percentage consensus was at a similar level.
BVXV was analyzed by 7 analysts. More opinions would make the average more meaningful.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2022-01-26Aegis CapitalInitiate Buy

Next Earnings Forecast Details

Next Earnings Details

Release Date
N/A
Period
Q3 / 2023
EPS Estimate
-$1.01
Revenue Estimate
Revenue Q2Q
N/A
EPS Q2Q
-10,198.00%
Number of Analysts
3

Next Earnings Revisions

Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%

Next Earnings Summary

→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2022 - 2024

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Revenue
YoY % growth
BVXV revenue by date.BVXV revenue by date.
N/AN/AN/A
EBITDA
YoY % growth
BVXV ebitda by date.BVXV ebitda by date.
-10.67M-11.28M
-5.72%		-23.22M
-105.85%		-76.81M
-230.79%		-76.7M
0.14%		9.77M
112.74%		-8.878M
-190.87%		N/AN/AN/A
EBIT
YoY % growth
BVXV ebit by date.BVXV ebit by date.
-11.3M-11.9M
-5.31%		-23.66M
-98.82%		-77.07M
-225.74%		-78.35M
-1.66%		7.33M
109.36%		-9.516M
-229.83%		N/A
-43.64%		N/A
6.03%		N/A
-58.82%
Operating Margin
BVXV operating margin by date.BVXV operating margin by date.
N/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
EPS
YoY % growth
BVXV eps by date.BVXV eps by date.
N/AN/A
98.72%		N/A
-1,200.00%		N/A
61.54%		N/A
104.90%		-1.26
-5,136.00%		N/A
-240.27%		N/A
99.29%		N/A
-8,400.00%		N/A
92.16%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q3 / 23 Q4 / 23
EPS
Q2Q % growth		-1.01
-10,198.00%		-1.13
-1,010.00%
Revenue
Q2Q % growth
EBITDA
Q2Q % growth		N/AN/A
EBIT
Q2Q % growth		-2.907M
-384.39%		-3.06M
4.00%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

BVXV Yearly EPS VS EstimatesBVXV Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2 -4 -6

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
24.98%
EPS Next 5 Year
N/A

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

BIONDVAX PHARMACEUTICALS-ADR / BVXV Forecast FAQ

What is the average price target for BIONDVAX PHARMACEUTICALS-ADR (BVXV) stock?

7 analysts have analysed BVXV and the average price target is 39.78 USD. This implies a price increase of 2825% is expected in the next year compared to the current price of 1.36.

What are the consensus estimates for BVXV stock next earnings?

The consensus EPS estimate for the next earnings of BIONDVAX PHARMACEUTICALS-ADR (BVXV) is -1.01 USD and the consensus revenue estimate is 0 USD.

How many analysts cover BIONDVAX PHARMACEUTICALS-ADR (BVXV) stock?

The number of analysts covering BIONDVAX PHARMACEUTICALS-ADR (BVXV) is 7.